These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 16038624)
1. Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial. Luo C; He ML; Bohlin L Acta Pharmacol Sin; 2005 Aug; 26(8):926-33. PubMed ID: 16038624 [TBL] [Abstract][Full Text] [Related]
2. Surface plasmon resonance studies and biochemical evaluation of a potent peptide inhibitor against cyclooxygenase-2 as an anti-inflammatory agent. Somvanshi RK; Kumar A; Kant S; Gupta D; Singh SB; Das U; Srinivasan A; Singh TP; Dey S Biochem Biophys Res Commun; 2007 Sep; 361(1):37-42. PubMed ID: 17640617 [TBL] [Abstract][Full Text] [Related]
3. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray? Hersh EV; Lally ET; Moore PA Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531 [TBL] [Abstract][Full Text] [Related]
4. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Kean WF; Buchanan WW Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389 [TBL] [Abstract][Full Text] [Related]
5. The effects of intrathecal cyclooxygenase-1, cyclooxygenase-2, or nonselective inhibitors on pain behavior and spinal Fos-like immunoreactivity. Lee IO; Seo Y Anesth Analg; 2008 Mar; 106(3):972-7, table of contents. PubMed ID: 18292448 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: a novel class of cyclooxygenase-2 inhibitors. Chen QH; Rao PN; Knaus EE Bioorg Med Chem; 2005 Dec; 13(23):6425-34. PubMed ID: 16099663 [TBL] [Abstract][Full Text] [Related]
7. The search for new COX-2 inhibitors: a review of 2002 - 2008 patents. Ramalho TC; Rocha M; da Cunha EF; Freitas MP Expert Opin Ther Pat; 2009 Sep; 19(9):1193-228. PubMed ID: 19563267 [TBL] [Abstract][Full Text] [Related]
8. Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors. Huntjens DR; Spalding DJ; Danhof M; Della Pasqua OE Eur J Pain; 2009 May; 13(5):448-57. PubMed ID: 18774319 [TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity. Biava M; Porretta GC; Poce G; Supino S; Forli S; Rovini M; Cappelli A; Manetti F; Botta M; Sautebin L; Rossi A; Pergola C; Ghelardini C; Vivoli E; Makovec F; Anzellotti P; Patrignani P; Anzini M J Med Chem; 2007 Nov; 50(22):5403-11. PubMed ID: 17915854 [TBL] [Abstract][Full Text] [Related]
10. Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib. Urdaneta A; Siso A; Urdaneta B; Cardenas R; Quintero L; Avila R; Suarez-Roca H Brain Res Bull; 2009 Aug; 80(1-2):56-61. PubMed ID: 19463915 [TBL] [Abstract][Full Text] [Related]
11. Perspective assessment of COX-1 and COX-2 selectivity of nonsteroidal anti-inflammatory drugs from clinical practice: use of genetic function approximation. Zambre AP; Ganure AL; Shinde DB; Kulkarni VM J Chem Inf Model; 2007; 47(2):635-43. PubMed ID: 17256838 [TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Zarghi A; Kakhgi S; Hadipoor A; Daraee B; Dadrass OG; Hedayati M Bioorg Med Chem Lett; 2008 Feb; 18(4):1336-9. PubMed ID: 18226898 [TBL] [Abstract][Full Text] [Related]
14. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Fries S; Grosser T; Price TS; Lawson JA; Kapoor S; DeMarco S; Pletcher MT; Wiltshire T; FitzGerald GA Gastroenterology; 2006 Jan; 130(1):55-64. PubMed ID: 16401468 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Gierse J; Nickols M; Leahy K; Warner J; Zhang Y; Cortes-Burgos L; Carter J; Seibert K; Masferrer J Eur J Pharmacol; 2008 Jun; 588(1):93-8. PubMed ID: 18457826 [TBL] [Abstract][Full Text] [Related]
16. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Waterbury LD; Silliman D; Jolas T Curr Med Res Opin; 2006 Jun; 22(6):1133-40. PubMed ID: 16846546 [TBL] [Abstract][Full Text] [Related]
17. The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame. Salinas G; Rangasetty UC; Uretsky BF; Birnbaum Y J Cardiovasc Pharmacol Ther; 2007 Jun; 12(2):98-111. PubMed ID: 17562780 [TBL] [Abstract][Full Text] [Related]
18. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455 [TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 inhibitors: what went wrong? James MJ; Cleland LG Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group. Crofford LJ; Breyer MD; Strand CV; Rushitzka F; Brune K; Farkouh ME; Simon LS J Rheumatol; 2006 Jul; 33(7):1403-8. PubMed ID: 16724374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]